Literature DB >> 25481767

Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease.

María Concepción García1, Valentina Cinquina2, Cristina Palomo-Garo1, Alberto Rábano3, Javier Fernández-Ruiz4.   

Abstract

It is well-demonstrated that cannabinoid CB2 receptors located in glial cells are up-regulated in neurodegenerative disorders serving as a target to control glial influences to neurons. Recent evidence indicates that CB2 receptors may be also located in certain neuronal subpopulations and serve as a marker of neuronal losses. We investigated this possibility in the post-mortem substantia nigra of Parkinson's disease (PD) patients and controls. Immunostaining for the CB2 receptor was found in tyrosine hydroxylase-positive neurons in the substantia nigra, a fact confirmed with double-staining analyses. The signal was found in controls but also in PD patients, in which CB2 receptor labelling was significantly lower, in parallel to the losses of these neurons experienced in the disease. These data show for the first time that CB2 receptors are located in tyrosine hydroxylase-containing neurons in the substantia nigra at levels significantly lower in PD patients compared to controls.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Basal ganglia; CB(2) receptors; Cannabinoids; Parkinson’s disease; Tyrosine hydroxylase-containing neurons

Mesh:

Substances:

Year:  2014        PMID: 25481767     DOI: 10.1016/j.neulet.2014.12.003

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  32 in total

Review 1.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

2.  Neuroprotective Effect of JZL184 in MPP(+)-Treated SH-SY5Y Cells Through CB2 Receptors.

Authors:  María S Aymerich; Estefanía Rojo-Bustamante; Carmen Molina; Marta Celorrio; Juan A Sánchez-Arias; Rafael Franco
Journal:  Mol Neurobiol       Date:  2015-05-15       Impact factor: 5.590

3.  Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.

Authors:  Shaness A Grenald; Madison A Young; Yue Wang; Michael H Ossipov; Mohab M Ibrahim; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Neuropharmacology       Date:  2016-12-20       Impact factor: 5.250

4.  Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Progress in brain cannabinoid CB2 receptor research: From genes to behavior.

Authors:  Chloe J Jordan; Zheng-Xiong Xi
Journal:  Neurosci Biobehav Rev       Date:  2019-01-03       Impact factor: 8.989

Review 6.  Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.

Authors:  Concepción García; Cristina Palomo-Garo; Yolanda Gómez-Gálvez; Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2015-07-31       Impact factor: 8.739

7.  Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease.

Authors:  Francisco Navarrete; M Salud García-Gutiérrez; Auxiliadora Aracil-Fernández; José L Lanciego; Jorge Manzanares
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

8.  Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain.

Authors:  Glòria Salort; María Álvaro-Bartolomé; Jesús A García-Sevilla
Journal:  Psychopharmacology (Berl)       Date:  2017-01-26       Impact factor: 4.530

9.  The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders.

Authors:  Qing Xin; Fei Xu; Devin H Taylor; Jing-Fu Zhao; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2020-10-06       Impact factor: 6.150

Review 10.  Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.

Authors:  Javier Fernández-Ruiz; María A Moro; José Martínez-Orgado
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.